Significance of common variants on human chromosome 8q24 in relation to the risk of prostate cancer in native Japanese men

Miao Liu1, Takayuki Kurosaki1, Motofumi Suzuki*1, Yutaka Enomoto1, Hiroaki Nishimatsu1, Tomio Arai2, Motoji Sawabe2, Takayuki Hosoi3, Yukio Homma1 and Tadaichi Kitamura1,4

Address: 1Department of Urology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan, 2Department of Pathology, Tokyo Metropolitan Geriatric Hospital, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan, 3Department of Advanced Medicine, National Center for Geriatrics and Gerontology, 36-3 Gengo, Morio-cho, Ohtsu, Aichi 474-8511, Japan and 4Department of Urology, Asoka Hospital, 1-18-1 Sumiyoshi, Koutou-ku, Tokyo 135-0002, Japan

Email: Miao Liu - hndfh20012003@yahoo.co.jp; Takayuki Kurosaki - kurosan@sb3.so-net.ne.jp; Motofumi Suzuki* - SUZUKIM-URO@h.u-tokyo.ac.jp; Yutaka Enomoto - yenomoto-ty@umin.ac.jp; Hiroaki Nishimatsu - nishimatsu-uro@h.u-tokyo.ac.jp; Tomio Arai - arai@tmig.or.jp; Motoji Sawabe - sawabe@tmig.or.jp; Takayuki Hosoi - hosworld@cb3.so-net.ne.jp; Yukio Homma - homma-uro@umin.ac.jp; Tadaichi Kitamura - tadkitamura-ty@umin.ac.jp

* Corresponding author

Abstract

Background: Common variants on human chromosome 8q24, rs1447295 (C/A) and rs6983267 (T/G), have been recently linked to the prevalence of prostate cancer in European and American populations. Here, we evaluated whether the single-nucleotide polymorphisms rs1447295 and rs6983267 were associated with the risk of sporadic prostate cancer as well as latent prostate cancer in a native Japanese population.

Results: We analyzed genomic DNA samples from 391 sporadic prostate cancer patients, 323 controls who had died from causes unrelated to cancer and 112 Japanese men who were diagnosed as having latent prostate cancer based on autopsy results. The polymorphisms were determined by allelic discrimination using a fluorescent-based TaqMan assay. The A allele of rs1447295 was significantly associated with the risk of sporadic prostate cancer (p = 0.04; age-adjusted OR, 1.34), while the G allele of rs6983267 showed a trend towards being a high-risk allele (p = 0.06; age-adjusted OR, 1.27). No significant difference between these two polymorphisms and the risk of latent prostate cancer was observed in the present Japanese population.

Conclusion: Known variants on human chromosome 8q24 may be risk factors for sporadic prostate cancer in native Japanese men.

Background

The incidence of prostate cancer is widely known to be much lower in Asian men than in Western men [1]. Recently, genome-wide association studies have revealed a close relation between variants on human chromosome 8q24 and the risk of prostate cancer [2-13]. In 2006, Amundadottir et al. [2] first identified a region on chromosome 8q24 that was possibly linked to prostate cancer in Icelandic men. Subsequently, Freedman et al. [3] confirmed an association between rs1447295 and the risk of...
prostate cancer in another ethnic cohort study. In yet another study, the prevalence of the rs1447295 polymorphism associated with prostate cancer was investigated in a population of Indian-born Asian Indians who had emigrated from India and were living in the United States [14]. In 2007, Haiman et al. [8] and Yeager et al. [9] showed a strong association between rs6983267 and the risk of prostate cancer. Their investigations included African Americans, Latino Americans, European Americans, Japanese Americans, native Hawaiians, Australians, Swedes, Icelanders, and the British, but not native Japanese or other East Asian men. Thus, we felt that it was important to replicate the study in a population of native Japanese subjects to better understand the disparities in prostate cancer risk among different ethnicities.

The characteristics of germline genetic polymorphisms among patients with latent prostate cancer diagnosed at the time of autopsy (LPCa) remain unknown. Stamey et al. first proposed the pathologic entity of clinically diagnosed latent prostate cancers, which are defined as clinically insignificant cancers [15]. Strictly speaking, ‘insignificant prostate cancer’ is not the same as ‘LPCa’, and a comparative genetic analysis of clinically diagnosed sporadic prostate cancer (SPCa) and LPCa might be useful for a better understanding of the nature of this disease. From this viewpoint, we also included LPCa subjects in the present study to examine the genetic differences between SPCa and LPCa patients.

Results
The characteristics of the control, SPCa, and LPCa groups are shown in Table 1. The age distributions of the control, SPCa, and LPCa groups were significantly different (p < 0.01). The T-stage distributions in the SPCa and LPCa groups were also significantly different (p < 0.01). The Gleason score distributions in the SPCa and LPCa groups were not significantly different (p = 0.49). Genotyping assays were successfully performed in all the subjects. Table 2 shows the distributions of the genotypes and alleles of the rs1447295 and rs6983267 polymorphisms. The genotype distributions for each SNP were consistent with Hardy-Weinberg equilibrium (HWE).

Compared with the major allele homozygous genotype as a reference, both the CA genotype of rs1447295 (p = 0.02; age-adjusted OR, 1.54; 95% CI, 1.08 – 2.21) and the GG genotype of rs6983267 (p = 7.0 × 10⁻³; age-adjusted OR, 2.21; 95% CI, 1.24 – 4.03) were significantly associated with the risk of SPCa. Moreover, the CA + AA genotypes of rs1447295 was also significantly associated with the risk of SPCa (p = 0.02; age-adjusted OR, 1.50; 95% CI, 1.07 – 2.11). In allele-wise analyses, the A allele of rs1447295 was significantly associated with the risk of prostate cancer (p = 0.04; age-adjusted OR, 1.34; 95% CI, 1.01 – 1.79), while the G allele of rs6983267 showed a tendency towards an increase in the risk of prostate cancer (P = 0.06; age-adjusted OR, 1.27; 95% CI, 0.99 – 1.62). One hundred and twelve patients among 1,179 autopsied men were diagnosed as having LPCa (9.5%). No significant differences were observed between the control and the LPCa patients (Table 3).

After stratification according to the Gleason score, T-stage, and serum prostate specific antigen (PSA) levels at the time of diagnosis, the frequencies of the CA and CA+AA genotypes of rs1447295 were observed significantly higher in SPCa patients with a Gleason score ≤7, a T-stage of T3 or T4, and a serum PSA level ≥20 ng/mL; meanwhile, the frequency of the GG genotype of rs6983267 was observed significantly higher in SPCa patients with a Gleason score ≥8, a T-stage of T1 or T2, and a serum PSA

Table 1: Characteristics of control, SPCa, and LPCa

|                | Control          | SPCa            | LPCa            | p value |
|----------------|------------------|-----------------|-----------------|---------|
| Age            |                  |                 |                 |         |
| median         |                  | 71              | 81              | < 0.01  |
| range          | 49 – 100         | 48 – 89         | 66 – 98         |         |
| T-stage        |                  |                 |                 |         |
| T1 or T2       | 167              | 102             |                 | < 0.01  |
| T3 or T4       | 224              | 5               |                 |         |
| unknown        | 0                | 5               |                 |         |
| Gleason score  |                  |                 |                 |         |
| ≤7             | 241 (92)         | 62              |                 |         |
| ≥8             | 150 (34)         | 45              |                 | 0.49    |
| unknown        | 0                | 5               |                 |         |

*aNumbers of patients with SPCa who were undergone radical prostatectomy are described in the parenthesis.
—, not applicable.
rs13254738, rs6983561, broad11934905, rs7000448 [8], such as DG8S737 [2,8], rs16901979 [7,11], associations with other genetic markers on chromosome prostate cancer in African Americans; however, positive
rs1447295 nor rs6983267 was associated with the risk of previously reported for Japanese Americans [3,8]. Neither
effects found in our study were very similar to those previ-
frequencies of the risk alleles and the magnitudes of the prostate cancer susceptibility in multi-ethnic studies. The
table of allele-wise analyses for prostate cancer in native Japanese
In 2008, Terada et al. [16] initially studied 507 patients with prostate cancer and 511 controls to determine the association between these common variants on chromosome 8q24 and the risk of prostate cancer in a native Japanese population. For their Japanese subjects, the A allele of rs1447295 was significantly associated with the risk of prostate cancer, while the G allele of rs6983267 was associated with the risk of prostatic enlargement rather than prostate cancer. Their findings for rs6983267 differed from the results reported by Haiman et al. [8] reported a significant association between these two factors (OR, 1.22; 95% CI, 1.05–1.42) in a study sample of 1,450 Japanese-Americans (722 patients with SPCa and 728 controls). The disparity between the results of their report and ours might have been caused by the different sample sizes.
level $\geq$ 20 ng/mL (Table 4). We also investigated a combined model examining the joint effect of both rs1447295 and rs6983267 on the prostate cancer risk. Individuals with SPCa who carried both the CA (rs1447295) and the GG (rs6983267) genotypes had a significantly higher risk of prostate cancer ($p = 0.03$; age-adjusted OR, 2.74; 95% CI, 1.13 – 7.17) (Table 5).

Discussion
The present case-controlled study investigated the relation between variants on human chromosome 8q24 and the risk of sporadic and latent prostate cancer in native Japanese men. We confirmed that the rs1447295 and rs6983267 polymorphisms were significantly associated with the risk of sporadic prostate cancer in native Japanese men. Table 6 shows the results of allele-wise analyses for prostate cancer susceptibility in multi-ethnic studies. The frequencies of the risk alleles and the magnitudes of the effects found in our study were very similar to those previously reported for Japanese Americans [3,8]. Neither rs1447295 nor rs6983267 was associated with the risk of prostate cancer in African Americans; however, positive associations with other genetic markers on chromosome 8, such as DG8S737 [2,8], rs16901979 [7,11], rs13254738, rs6983561, broad11934905, rs7000448 [8], and rs7008482 [11], were also reported in these subjects. Whether these markers might also be valid for native Japanese men should be confirmed in future studies. In a genome-wide association study in subjects of European ancestry [9], the ORs of the CA and AA genotypes of rs1447295 were 1.43 and 2.23, respectively. In our results, patients with the CA genotype of rs1447295 were more likely to have prostate cancer ($p = 0.02$; age-adjusted OR, 1.54; 95% CI, 1.08–2.21); however, the AA genotype was not significantly associated with prostate cancer in the present study ($p = 0.50$; age-adjusted OR, 1.50; 95% CI, 0.62–2.73). In addition, the CA+AA genotypes of rs1447295 were observed more frequently in the SPCa group ($p = 0.02$; age-adjusted OR, 1.50; 95% CI, 1.07–2.11), similar to the results of a previous study conducted in Australian men [4]. As for the rs6983267 polymorphism, we could not find any significant association between the G allele and SPCa ($p = 0.06$; age-adjusted OR, 1.27, 95% CI: 0.99–1.62), although Haiman et al. [8] reported a significant association between these two factors (OR, 1.22; 95% CI, 1.05–1.42) in a study sample of 1,450 Japanese-Americans (722 patients with SPCa and 728 controls). The disparity between the results of their report and ours might have been caused by the different sample sizes.

Table 2: Genotypic and allelic frequencies of rs1447295 and rs6983267 polymorphisms

| Genotype | Control (%) | SPCa (%) | LPCa (%) |
|----------|-------------|----------|----------|
| (N = 23) | (N = 391)   | (N = 112) |
| rs1447295 |             |          |          |
| CC       | 218 (67.5)  | 217 (55.5) | 71 (63.4) |
| CA       | 89 (27.5)   | 149 (38.1) | 34 (30.4) |
| AA       | 16 (5.0)    | 25 (6.4)  | 7 (6.2)   |
| rs6983267 |             |          |          |
| TT       | 147 (45.5)  | 151 (38.6) | 48 (42.9) |
| TG       | 151 (46.8)  | 181 (46.3) | 53 (47.3) |
| GG       | 25 (7.7)    | 59 (15.1) | 11 (9.8)  |
| Allele   |             |          |          |
| Control (%) | (2N = 646) | (2N = 782) | (2N = 224) |
| rs1447295 |             |          |          |
| C        | 525 (81.3)  | 583 (74.6) | 176 (78.6) |
| A        | 121 (18.7)  | 199 (25.4) | 48 (21.4) |
| HWE      |             |          |          |
| chi-square | 2.91       | 0.01     | 1.09     |
| p value  | 0.09        | 0.93     | 0.30     |
| rs6983267 |             |          |          |
| T        | 445 (68.9)  | 483 (61.8) | 149 (66.5) |
| G        | 201 (31.1)  | 299 (38.2) | 75 (33.5) |
| HWE      |             |          |          |
| chi-square | 2.65       | 0.16     | 0.44     |
| p value  | 0.10        | 0.69     | 0.51     |

HWE, Hardy-Weinberg equilibrium.
OR, 2.74; 95% CI, 1.13–7.17). The accumulation of samples in collaboration with various international centers would be indispensable for the further study of such interactions.

The functional features of these polymorphisms are still unclear. The closest characterized gene is the proto-oncogene \textit{c-MYC}, located approximately 264 kb from rs1447295 [2,6]. Sato et al. [17] demonstrated that patients with additional increases in the \textit{c-MYC} copy number relative to the chromosome 8 centromere showed a more rapid disease progression and earlier death from cancer. Thus, clarifying the relation between \textit{c-MYC} amplification and the risk alleles among the polymorphic markers located in 8q24 is a crucial task.

To the best of our knowledge, no study to date has examined common variants on human chromosome 8 among subjects with LPCa. Our results suggested that the rs1447295 and rs6983267 polymorphisms were not associated with the risk of LPCa in native Japanese men. The frequencies of each genotype in these subjects and the controls were quite similar. We believe that such genetic research in subjects with LPCa may be useful for clarifying the genetic characteristics of clinically insignificant prostate cancer.

In Japan, the age-adjusted incidence rate of prostate cancer was determined to be 26.2 per 100,000 in 2001 [18], while that in Japanese Americans living in California was determined to be 103.7 per 100,000 (2000 to 2002) [1]. Denis et al. [19] suggested that low intakes of vitamin E, selenium, lignans and isoflavonoids affected the tumorigenesis risk of prostate cancer. Marks et al. [20] reported that Japanese Americans had more body fat, higher serum triglyceride levels, lower estradiol levels, and much lower soy-metabolite levels than native Japanese. Additionally, Bettuzzi et al. [21] and Kurahashi et al. [22] emphasized the protective effects of green tea constituents against the risk of prostate cancer. These findings suggest that we need to consider genetic and environmental factors, as well as nutrition, in our attempts to prevent prostate cancer.

This study had several limitations. First, our sample size was relatively small, and this might have influenced the robustness of the results. Further study using larger samples for both the case and control groups is necessary. Secondary, several pathologists at the affiliated hospitals had participated in the diagnosis of prostate cancer. Therefore, we cannot deny the inter-observer variability existed. Moreover, the data of Gleason score was underestimated, because two thirds of the pathological data from SPCa patients were obtained by biopsy.

Little is known about why the prevalence of prostate cancer is much lower in Asian populations than in other ethnicities. Researchers from Asia need to collaborate in addressing this issue.

**Conclusion** The present study demonstrates that polymorphisms on 8q24 are associated with the occurrence of prostate cancer.

---

**Table 3: Genotypic and allelic analyses of prostate cancer susceptibility**

| Genotype | Control vs. SPCa | p value | Control vs. LPCa | p value |
|----------|------------------|---------|------------------|---------|
| rs1447295 |                  |         |                  |         |
| CC       | 1.0 reference    | 1.0     | 1.0 reference    | 1.0     |
| CA       | 1.54 1.08–2.21   | 0.02    | 1.22 0.75–1.98   | 0.42    |
| AA       | 1.29 0.62–2.73   | 0.50    | 1.45 0.53–3.59   | 0.45    |
| CA + AA  | 1.50 1.07–2.11   | 0.02    | 1.25 0.79–1.97   | 0.33    |
| rs6983267 |                  |         |                  |         |
| TT       | 1.0 reference    | 1.0     | 1.0 reference    | 1.0     |
| TG       | 0.95 0.67–1.35   | 0.78    | 1.17 0.74–1.86   | 0.50    |
| GG       | 2.21 1.24–4.03   | 7.0 × 10⁻³| 1.40 0.62–3.03   | 0.40    |
| TG + GG  | 1.12 0.80–1.57   | 0.50    | 1.21 0.78–1.88   | 0.41    |

| Allele   | Control vs. SPCa | p value | Control vs. LPCa | p value |
|----------|------------------|---------|------------------|---------|
| rs1447295 |                  |         |                  |         |
| C        | 1.0 reference    | 1.0     | 1.0 reference    | 1.0     |
| A        | 1.34 1.01–1.79   | 0.04    | 1.23 0.84–1.79   | 0.29    |
| rs6983267 |                  |         |                  |         |
| T        | 1.0 reference    | 1.0     | 1.0 reference    | 1.0     |
| G        | 1.27 0.99–1.62   | 0.06    | 1.17 0.84–1.62   | 0.35    |

**OR**, Age-adjusted odds ratio.

---
Table 4: Prostate cancer susceptibility stratified by Gleason score, T-stage, and serum PSA levels at diagnosis (control vs. SPCa)

| Genotype | Glyasseon score ≤ 7 (N = 241) |  | Glyasseon score ≥ 8 (N = 150) |  |
|----------|-----------------------------|---|-----------------------------|---|
|          | OR*                        | 95% CI | p value | OR*                        | 95% CI | p value |
| rs1447295 |                |              |        |              |        |        |
| CC       | 1.0 reference            | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| CA       | 1.62 0.88 – 2.17        | 0.15 1.70 | 0.05 1.14 – 2.54 | 0.01 1.11 – 2.41 |
| AA       | 1.34 0.53 – 3.29        | 0.53 1.28 | 0.35 0.95 – 2.95 | 0.57 1.11 – 2.41 |
| CA + AA  | 1.38 0.90 – 2.11        | 0.14 1.64 | 0.11 1.11 – 2.41 | 0.01 1.11 – 2.41 |
| rs6983267 |                |              |        |              |        |        |
| TT       | 1.0 reference            | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| TG       | 0.96 0.61 – 1.51        | 0.87 0.91 | 0.61 1.36 | 0.65 1.36 |
| GG       | 2.68 1.37 – 5.30        | 4.0 x 10^-3 1.69 | 0.87 3.31 | 0.12 3.31 |
| TG + GG  | 1.19 0.78 – 1.83        | 0.42 1.02 | 0.69 1.49 | 0.93 1.49 |
|          |              |              |        |              |        |        |
| rs1447295 |                |              |        |              |        |        |
| CC       | 1.0 reference            | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| CA       | 1.46 0.95 – 2.23        | 0.08 1.71 | 1.12 2.60 | 0.01 2.60 |
| AA       | 0.97 0.37 – 2.44        | 0.95 1.69 | 0.74 3.83 | 0.21 3.83 |
| CA + AA  | 1.38 0.92 – 2.08        | 0.12 1.70 | 1.14 2.54 | 9.0 x 10^-3 2.54 |
| rs6983267 |                |              |        |              |        |        |
| TT       | 1.0 reference            | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| TG       | 0.96 0.63 – 1.47        | 0.86 0.92 | 0.60 1.40 | 0.69 1.40 |
| GG       | 1.46 0.72 – 2.96        | 0.30 2.74 | 1.45 5.24 | 2.0 x 10^-3 5.24 |
| TG + GG  | 1.03 0.69 – 1.55        | 0.88 1.16 | 0.78 1.73 | 0.47 1.73 |
|          |              |              |        |              |        |        |
| rs1447295 |                |              |        |              |        |        |
| CC       | 1.0 reference            | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| CA       | 1.69 0.98 – 2.91        | 0.06 1.54 | 1.06 2.25 | 0.02 2.25 |
| AA       | 1.39 0.44 – 3.99        | 0.56 1.28 | 0.59 2.81 | 0.53 2.81 |
| CA + AA  | 1.64 0.97 – 2.75        | 0.06 1.50 | 1.05 2.15 | 0.03 2.15 |
| rs6983267 |                |              |        |              |        |        |
| TT       | 1.0 reference            | 1.0 reference | 1.0 reference | 1.0 reference | 1.0 reference |
| TG       | 0.99 0.58 – 1.71        | 0.97 0.93 | 0.64 1.36 | 0.72 1.36 |
| GG       | 1.45 0.58 – 3.46        | 0.42 2.32 | 1.29 4.26 | 0.01 4.26 |
| TG + GG  | 1.05 0.63 – 1.78        | 0.85 1.12 | 0.79 1.60 | 0.52 1.60 |

OR* = Age-adjusted odds ratio.

*Aggressive, Gleason score ≥ 8, and/or T-stage T3 or T4, and/or PSA ≥ 20 ng/mL.
in the native Japanese population. Our results confirm that these polymorphisms are closely related to the risk of SPCa; however, we did not observe an association between these polymorphisms and the risk of LPCa. One limitation of our study was that the number of our samples was relatively small; consequently, studies with larger populations and family-based analyses are needed in the future.

Methods

Study design

A total of 391 Japanese patients with SPCa who were treated at the Department of Urology at the University of Tokyo Hospital or at our affiliated hospitals located in the Kanto area of Japan between January 1999 and August 2007 were enrolled. One hundred twenty-six cases underwent a radical prostatectomy and the remaining cases were treated with androgen-deprivation therapy. Adenocarcinoma of the prostate was pathologically confirmed in all the cases, and the Gleason score was also evaluated by pathologists working at each hospital. The clinical T stage of the patients with SPCa was evaluated based on a digital rectal examination, transrectal ultrasonography, pelvic computed tomography, and pathological findings according to the 2002 TNM staging system for cancer [23]. The serum PSA levels at diagnosis were also measured. Patients with a family history of prostate cancer were carefully excluded from this study. The mean age of the SPCa patients was 70.7 ± 8.0 years (median, 71 years; range, 48 to 89 years). Genomic DNA samples were extracted from peripheral blood specimens of these patients. The study was conducted with the approval of the Ethics Committee of the University of Tokyo and the internal review board of each of the affiliated hospitals. Written informed consent was obtained from the patients’ family members under the Act of Postmortem Examination. This study was also reviewed and approved by the Ethics Committee of the Tokyo Metropolitan Geriatric Hospital. Moreover, this study was carried out in compliance with the Helsinki Declaration.

Genotyping assay

Genotyping of the rs1447295 and rs6983267 polymorphisms was conducted using a TaqMan assay with an ABI PRISM 7000 or 7300 sequence detection system (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. We adjusted the concentration of the DNA solution to 100 ng/mL before using it. The sequences of the specific primers and TaqMan probes and the conditions for quantitative real-time polymerase chain reaction were obtained from the website of the National Cancer Institute [http://snp500cancer.nci.nih.gov/snp.cfm].

Statistical analysis

All the statistical analyses were conducted using JMP software, version 7.0 (SAS, Cary, NC, USA). The chi-square test was used to examine Hardy-Weinberg equilibrium (HWE) and to compare the distribution of the genotypes and alleles among the control, SPCa and LPCa patients. To estimate the odds ratios (ORs) and 95% confidence intervals (CIs), logistic regression analyses were performed using age as a covariate to statistically adjust for its potential confounding effects. Additionally, we estimated ORs and 95%CIs after stratification according to the Gleason score, T-stage, and serum PSA levels at diagnosis, as just as Terada et al. reported [16]. P values less than 0.05 were considered significant.

Abbreviations

LPCa: latent prostate cancer diagnosed at the time of autopsy; SPCa: clinically diagnosed sporadic prostate cancer; HWE: Hardy-Weinberg equilibrium; PSA: prostate specific antigen; OR: odds ratio; CI: confidence interval.

Authors’ contributions

ML carried out the genotyping assay, data analysis, and drafted the manuscript. TK1 carried out the genotyping
Table 6: Allele-wise analyses for prostate cancer risk in the multiethnic studies

| Author (Year)       | N cases/N controls | Study population   | Cases | Controls | OR    | 95% CI    | p value |
|---------------------|--------------------|--------------------|-------|----------|-------|-----------|---------|
| Amundadottir, et al. (2006) | 1291/997 | Iceland            | 0.17  | 0.11     | 1.72  | —         | 1.7 × 10^-9 |
|                     | 1435/779          | Sweden             | 0.16  | 0.13     | 1.29  | —         | 4.5 × 10^-3 |
|                     | 458/247           | European Americans | 0.13  | 0.08     | 1.66  | —         | 6.7 × 10^-2 |
|                     | 246/352           | African Americans  | 0.34  | 0.31     | 1.15  | —         | 0.29     |
| Freedman, et al. (2006) | 70/68             | Native Hawaiians   | 0.37  | 0.16     | 3.02  | 1.66 – 5.50 | 1.5 × 10^-4 |
|                     | 449/465           | Japanese Americans | 0.24  | 0.17     | 1.48  | 1.18 – 1.86 | 3.4 × 10^-4 |
|                     | 640/567           | Latino Americans   | 0.14  | 0.10     | 1.48  | 1.14 – 1.91 | 1.4 × 10^-3 |
|                     | 455/447           | European Americans | 0.13  | 0.10     | 1.35  | 1.01 – 1.80 | 0.02     |
|                     | 989/804           | African Americans  | —     | —        | 1.05  | 0.95 – 1.16 | 0.15     |
| Wang, et al. (2007)  | 491/545           | Caucasians         | 0.12  | 0.10     | 1.16  | 0.85 – 1.58 | 0.25     |
|                     | 435/545           | Caucasians*        | 0.17  | 0.10     | 1.93  | 1.37 – 2.72 | 4.0 × 10^-3 |
| Gudmundsson, et al. (2007) | 1453/3064    | Iceland            | 0.17  | 0.10     | 1.71  | 1.49 – 1.95 | 1.6 × 10^-14 |
|                     | 385/892           | Spain              | 0.10  | 0.07     | 1.44  | 1.07 – 1.94 | 1.7 × 10^-2 |
|                     | 367/1302          | The Netherlands     | 0.14  | 0.11     | 1.39  | 1.09 – 1.78 | 9.0 × 10^-3 |
|                     | 373/372           | African Americans  | 0.32  | 0.31     | 1.01  | 0.81 – 1.25 | 0.96    |
| Haiman, et al. (2007) | 1614/837         | African Americans  | —     | —        | —     | —         | —       |
|                     | 722/728           | Japanese Americans | —     | —        | —     | —         | —       |
|                     | 111/112           | Native Hawaiians   | —     | —        | —     | —         | —       |
|                     | 637/633           | Latino Americans   | —     | —        | —     | —         | —       |
|                     | 1182/942          | European Americans | —     | —        | —     | —         | —       |
| Robbins, et al. (2007) | 490/567         | African Americans  | 0.34  | 0.31     | 1.40  | 0.70 – 1.30 | 0.13     |
| Present study (2009) | 391/323           | Native Japanese    | 0.25  | 0.19     | 1.34  | 1.01 – 1.79 | 0.04     |

rs6983267

| Author (Year)       | N cases/N controls | Study population   | Cases | Controls | OR    | 95% CI    | p value |
|---------------------|--------------------|--------------------|-------|----------|-------|-----------|---------|
| Amundadottir, et al. (2006) | 1291/997 | Iceland            | —     | —        | —     | —         | —       |
|                     | 1435/779          | Sweden             | —     | —        | —     | —         | —       |
|                     | 458/247           | European Americans | —     | —        | —     | —         | —       |
|                     | 246/352           | African Americans  | —     | —        | —     | —         | —       |
| Freedman, et al. (2006) | 70/68             | Native Hawaiians   | —     | —        | —     | —         | —       |
|                     | 449/465           | Japanese Americans | —     | —        | —     | —         | —       |
|                     | 640/567           | Latino Americans   | —     | —        | —     | —         | —       |
|                     | 455/447           | European Americans | —     | —        | —     | —         | —       |
|                     | 989/804           | African Americans  | —     | —        | —     | —         | —       |
| Wang, et al. (2007)  | 491/545           | Caucasians         | —     | —        | —     | —         | —       |
|                     | 435/545           | Caucasians*        | —     | —        | —     | —         | —       |
| Gudmundsson, et al. (2007) | 1453/3064    | Iceland            | —     | —        | —     | —         | —       |
|                     | 385/892           | Spain              | —     | —        | —     | —         | —       |
|                     | 367/1302          | The Netherlands     | —     | —        | —     | —         | —       |
|                     | 373/372           | African Americans  | —     | —        | —     | —         | —       |
| Haiman, et al. (2007) | 1614/837         | African Americans  | —     | —        | —     | —         | —       |
|                     | 722/728           | Japanese Americans | —     | —        | —     | —         | —       |
|                     | 111/112           | Native Hawaiians   | —     | —        | —     | —         | —       |
|                     | 637/633           | Latino Americans   | —     | —        | —     | —         | —       |
|                     | 1182/942          | European Americans | —     | —        | —     | —         | —       |
| Robbins, et al. (2007) | 490/567         | African Americans  | 0.90† | 0.84     | 1.43  | 1.17 – 1.75 | —       |
| Present study (2009) | 391/323           | Native Japanese    | 0.38  | 0.31     | 1.27  | 0.99 – 1.62 | 0.06     |

—, not applicable.
* Familial prostate cancer cases.
† We calculated the G allele frequencies of rs6983267. Genotype data were obtained from the supplementary Table 3 (reference No. 8).
assay. YE analyzed and interpreted the data. TA, MS2, and TH collected the control and latent prostate cancer subjects and interpreted the data. TK2 and MS1 conceived the study. MS1 was also involved in the statistical analysis and drafting of the manuscript. HN was involved in the manuscript’s revision. TK2 and YH approved the manuscript for publication. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by a grant from the Japanese Foundation for Prostate Research. The sponsor of the study had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the manuscript for publication. The authors thank all the investigators who contributed to this study.

References
1. McCracken M, Olsen M, Chen MS Jr, Jamal A, Thun M, Cokkinides V, Deapen D, Ward E: Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin 2007, 57:190-205.
2. Amundadottir LT, Sulem P, Gudmundsson J, Helgason A, Baker A, Arnarsson BA, Sigurdsson A, Benediktsson KR, Caieter J, Sainz J, Jakobsson M, Kostic J, Magnusdottir DN, Ghou S, Arnarsson K, Birgisdottir B, Le Roux L, Olsafisod A, Blondal T, Andresdottir M, Grettardottir OS, Berghorssson JT, Gudbjartsson D, Gyfaaason F, Thorleifsson G, Manolescu A, Kristjansson K, Geirsson G, Isaksson H, Douglas J, Johansson JE, Bailer K, Wiklund F, Montie JE, Yu X, Suarez BK, Ober C, Cooney KA, Gudjonson H, Catalona WJ, Einarsdottir KA, Barkardottir RB, Gukler JR, Kong A, Thorsteinsdottir U, Stefansson K: A common variant associated with prostate cancer in European and African populations. Nat Genet 2006, 38:652-638.
3. Freedman ML, Haiman CA, Patterson N, McDonald GJ, Tandon A, Waliszewska A, Penney K, Steen RG, Ariddie K, John EM, Oakley-Girvan I, Whittemore AS, Cooney KA, Ingles SA, Alstuhler D, Henderson BE, Reich D: Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 2006, 103:14068-14073.
4. Seveer TS, Hayes VM, Padilla EJ, English DR, Southey MC, Sutherland RL, Hopper JL, Giles GG: The Common Variant rs1447295 on Chromosome 8q24 and Prostate Cancer Risk: Results from an Australian Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev 2007, 16:610-617.
5. Saurimne M, Agulli I, Schaid DJ, Johansson B, McDonnell SK, Iwasaki S, Stanford JL, Ostrander EA: Confirmation of a positive association between prostate cancer risk and a locus at chromosome 8q24. Cancer Epidemiol Biomarkers Prev 2007, 16:809-814.
6. Wang L, McDonnell SK, Slusser JP, Hebbring SJ, Cunningham JM, Jacobsen SJ, Cerhan JR, Blute ML, Schaid DJ, Thibodeau SN: Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res 2007, 67:2944-2950.
7. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, Rafnar T, Berghorssson JT, Arnarsson BA, Baker A, Sigurdsson A, Benediktsson KR, Jakobsson M, Xu J, Blondal T, Kostic J, Sun J, Ghou S, Stacey SN, Mouy M, Saemundsdottir J, Backman VM, Kristjansson K, Tress A, Partin AW, Albers-Akker MT, Goddard ME, Schmid HP: Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Proc Natl Acad Sci USA 2006, 103:14068-14073.
8. Haiman CA, Patterson N, Friedman ML, Myers SR, Pike MC, Waliszewska A, Neubauer J, Tandon A, Schirmer C, McDonald GJ, Greenway SC, Stram DO, Le Marchand L, Kolone LN, Fraisco M, Wong D, Pooler LC, Ariddie K, Oakley-Girvan I, Whittemore AS, Cooney KA, John EM, Ingles SA, Alstuhler D, Henderson BE, Reich D: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 2007, 39:638-644.
9. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft P, Wacholder S, Minichello MJ, Fearnhead P, Yu K, Chatterjee N, Wang Z, Welch R, Staats BJ, Calle EE, Feigelson HS, Thun M, Rodriguez C, Albanes D, Virtamo J, Weirstein S, Schumacher FR, Giovannucci E, Willett WC, Cancel-Tassin G, Cusenot O, Valeri A, Andriole GL, Geimann EP, Tsuchiya N, Gerhard DS, Fraumeni JF Jr, Hoover R, Hunter DJ, Chanock SJ, Thomas G: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007, 39:645-649.
10. Zheng SL, Sun J, Cheng Y, Li G, Hsu FC, Zhu Y, Chang BL, Liu W, Kim JW, Turner AR, Gielzak M, Yan G, Isaacs SD, Wiley KE, Sauvageau J, Chen HS, Gurganos R, Mandela LG, Trock BJ, Gronberg H, Duggan D, Carpten JD, Partin AW, Walsh PC, Xu J, Isaacs WB: Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst 2007, 103:761-763.
11. Robbins C, Torres JB, Hooker S, Bonilla C, Hernandez W, Candreva A, Ahaghotu C, Kallie D, Carpten J: Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk factor. Genomics Res 2007, 17:1717-1722.
12. Sun J, Lange EM, Isaacs SD, Liu W, Wiley KE, Lange L, Gronberg H, Duggan D, Carpten JD, Walsh PC, Xu J, Chang BL, Isaacs WB, Zheng SL: Chromosome 8q24 risk variants in hereditary and non-hereditary prostate cancer patients. Prostate 2008, 68:489-497.
13. Mesana I, Rosenberg PS, Chen BE: PEGA: power calculator for case-control genetic association analyses. BMC Genet 2008, 9:36.
14. Pemberton TJ, Mehta NU, Witonsky D, Di Rienzo A, Allayee H, Conti DV, Patel PI: Prevalence of common disease-associated variants in Asian Indians. BMC Genet 2008, 9:12.
15. Shintay ME, Freilah PS, McNeil EA, Redwine EA, Whittemore AS, Schmid HP: Localization of prostate cancer. Cancer 1993, 71:933-938.
16. Terada N, Tsuchiya N, Ma Z, Shimizu Y, Kobayashi T, Nakamura E, Kamoto T, Hacubhi T, Ogawa O: Association of Genetic Polymorphisms at 8q24 With the Risk of Prostate Cancer in a Japanese Population. Prostate 2008, 68:1699-1695.
17. Sato H, Minei S, Hachii Y, Yoshida T, Takimoto Y: Fluorescence in situ hybridization analysis of c-myc amplification in stage T1N0M0 prostate cancer in Japanese patients. Int J Urol 2006, 13:763-766.
18. Center for Cancer Control and Information Services, National Cancer Center, Japan [http://ganjoho.ncc.go.jp/professional/statistics/statistics.html]..
19. Denis L, Morton HS, Griffiths K: Diet and its preventive role in prostate disease. Eur Urol 1999, 35:377-387.
20. Marks LS, Kojima M, Demarzo A, Beber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW: Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. Urology 2004, 64:765-771.
21. Benitez S, Brausi M, Rizzi F, Castagnetii G, Peracchia C, Corti A: Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: A preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
22. Kurihashi N, Sasazuki S, Iwasaki M, Inoue M, Tsugane S, JPHC Study Group: Green tea consumption and prostate cancer risk in Japanese men: A prospective study. Am J Epidemiol 2008, 167:71-77.
23. Sabin LH, Wittekind C, Ed: TNM classification of malignant Tumors, 6th edition. Wiley-Liss, New York; 2002.
24. Suzuki M, Kurosaki T, Araki T, Sawabe M, Hosot I, Kitamura T: The Val158Met polymorphism of the catechol-O-methyltransferase gene is not associated with the risk of sporadic or latent prostate cancer in Japanese men. Int J Urol 2007, 14:800-804.
25. Sawabe M, Araki T, Kasa infra A, Etsuki Y, Nakahara K, Hosot I, Orinom H, Takubo K, Murayama S, Tanaka N: Development of a geriatric autopsy database and Internet-based database of Japanese single nucleotide polymorphisms for geriatric research (JG-SNP). Mech Ageing Dev 2004, 125:557-562.